NVS — Novartis AG stock price, charts and financials

QT59Novartis AG

Novartis AG (NYSE: NVS) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
153.27
-0.40-0.26%
OverviewShort InterestFilings
NVSQT59Novartis AG·NYSE
153.27-0.26%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MRK+0.21%$128.04AMGN+2.94%$390.02ABBV-0.53%$243.80NVO-5.97%$44.28GILD+3.13%$135.25PFE+1.52%$25.41JNJ+0.20%$254.93BMY+0.64%$65.89
Snapshot
Index-P/E23.12EPS (ttm)6.63Insider Own-Shs Outstand1.90BPerf Week-4.12%
Market Cap291.32BForward P/E15.62EPS next Y9.81Insider Trans-Shs Float1.83BPerf Month-1.43%
Enterprise Value332.65BPEG2.18EPS next Q2.23Inst Own7.54%Short Float0.31%Perf Quarter5.98%
Income12.76BP/S5.24EPS this Y32.37%Inst Trans-Short Ratio3.30Perf Half Y1.48%
Sales55.63BP/B6.95EPS next Y11.78%ROA10.34%Short Interest5.71MPerf YTD11.17%
Book/sh22.07P/C37.88EPS next 5Y10.62%ROE29.64%52W High170.45 -10.08%Perf Year32.93%
Cash/sh4.05P/FCF18.65EPS past 3/5Y31.39% 15.36%ROIC13.38%52W Low113.48 35.06%Perf 3Y55.48%
Dividend Est.4.74 (3.09%)EV/EBITDA14.94Sales past 3/5Y8.04% 1.90%Gross Margin74.29%Volatility1.46% 1.68%Perf 5Y77.38%
Dividend TTM4.74 (3.09%)EV/Sales5.98EPS Y/Y TTM12.95%Oper. Margin29.86%ATR (14)3.25Perf 10Y119.49%
Dividend Ex-DateMar 11, 2026Quick Ratio0.67Sales Y/Y TTM7.57%Profit Margin23.09%RSI (14)47.55Recom2.84
Dividend Gr. 3/5Y6.30% 5.28%Current Ratio0.86EPS Q/Q-0.41%SMA20-0.76%Beta0.45Target Price170.00
Payout67.77%Debt/Eq0.80Sales Q/Q-2.82%SMA500.40%Rel Volume0.93Prev Close153.67
Employees75,267LT Debt/Eq0.67EarningsOct 27SMA2004.62%Avg Volume1.83MPrice153.27
IPO DateNov 07, 1996Option/ShortYes / YesEPS/Sales Surpr.10.95% 2.43%Net Debt/EBITDA1.88Volume1,706,408Change-0.26%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-26-26ReiteratedMorgan StanleyOverweight$143 → $170
Jan-06-26UpgradeBarclaysUnderweight → Equal Weight
Dec-10-25ReiteratedHSBCHold$106 → $112
Dec-08-25UpgradeJP MorganNeutral → Overweight
Dec-03-25ReiteratedMorgan StanleyEqual Weight$136 → $143
Oct-29-25ReiteratedCFRA$108 → $126
Sep-12-25DowngradeGoldman SachsNeutral → Sell
Feb-13-25DowngradeUBSBuy → Neutral
Nov-19-24DowngradeErste GroupBuy → Hold
Oct-30-24ReiteratedBMO CapitalMarket Perform$118 → $120
Latest News
Aug-01-26
Aug-01-2604:21AM
Axiom Investment Management LLC Takes Position in Novartis AG $NVSdefenseworld.net
Jul-31-26
Jul-31-2605:15PM
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month RunSeekingAlpha
Jul-30-26
Jul-30-2603:28AM
Ashton Thomas Securities LLC Makes New Investment in Novartis AG $NVSdefenseworld.net
Jul-29-26
Jul-29-2601:00PM
3 Dividend Stocks to Buy for a Lifetime of Passive Incomefool.com
Jul-27-26
Jul-27-2605:05AM
12,359 Shares in Novartis AG $NVS Bought by Entropy Technologies LPdefenseworld.net
04:18AM
Cetera Investment Advisers Buys 24,096 Shares of Novartis AG $NVSdefenseworld.net
Jul-24-26
Jul-24-2608:22PM
Regeneron: I'm Not Concerned About The Declining ROIC And Operating MarginsSeekingAlpha
Jul-22-26
Jul-22-2609:28AM
Novartis: The Buy Thesis Is Back (Rating Upgrade)seekingalpha.com
Jul-21-26
Jul-21-2605:43PM
Novartis AG (NVS) Q2 2026 Earnings Call Transcriptseekingalpha.com
05:16PM
Novartis CEO on 2Q Profit Beat, Investing in Pipelineyoutube.com
12:46PM
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Wellzacks.com
11:50AM
Q2 Earnings Pick Up Steam: GM, MMM, DHI & Morezacks.com
11:07AM
Novartis Q2 Earnings Call Highlightsmarketbeat.com
10:31AM
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metricszacks.com
08:50AM
5 Things to Know Before the Stock Market Opens on Tuesdayinvestopedia.com
Company

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Ownership
Total institutional ownership7.54%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue55,63554,81151,72246,66043,46143,97449,89848,67746,099
Cost of Goods Sold Incl. D&A14,22113,69012,82712,47211,58211,73515,12114,42514,510
Gross Profit41,41441,12238,89534,18831,87932,23934,77734,25231,589
Selling, General and Administrative Excl. Other13,12713,30612,56612,51712,19312,82714,19714,36913,717
Research and Development11,28010,74210,02211,3719,1728,6418,9809,4028,489
Other Operating Expense1601,7635312,5687151,4481,395980
Operating Income16,99217,07414,5449,7697,94610,05610,1529,0868,403
Interest Expense1,3901,1871,036876835905921903973
Unusual Expense
—————————
Non-Operating Income (Expense)-775491322306615,3796477576,665
Net Income Before Taxes15,52516,43613,6409,1237,17724,5309,8788,94014,095
Income Taxes2,7762,3971,7015511,1281,6251,8071,7931,295
Consolidated Net Income12,75914,05611,94114,8506,95524,0218,07211,73212,611
Net Income From Continuing Operations12,74914,03911,9398,5726,04922,9058,0717,14712,800
Net Income12,75914,05611,94114,8506,95524,0218,07211,73212,611
EPS (Recurring)6.667.255.927.153.1910.713.543.125.44
EPS (Basic, Before Extraordinaries)6.667.255.927.153.1910.713.543.125.44
EPS (Diluted)6.637.195.877.103.1710.633.523.085.38
EBITDA22,26022,98720,71518,25514,68230,91417,21115,61620,238
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio23.1219.1816.5814.2227.087.7925.3929.0913.34
Price To Sales Ratio5.254.883.804.494.314.224.084.223.61
Gross Margin74.4475.0375.2073.2773.3573.3169.7070.3768.52
Operating Margin30.5431.1528.1220.9418.2822.8720.3518.6718.23
Net Margin22.9325.6423.0931.8316.0054.6316.1824.1027.36
Shares Outstanding1,9051,9392,0182,0772,1812,2432,2772,2912,319
Market Capitalization291,979267,330196,372209,715187,239185,653203,473205,274166,481
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.